UNLABELLED: 2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. We previously described and validated a five-compartment model for thymidine incorporation into DNA in somatic tissues, but the effect of the blood-brain barrier on the transport of TdR and its metabolites necessitated further validation before it could be applied to brain tumors. METHODS: We investigated the behavior of the model under conditions experienced in the normal brain and brain tumors, performed sensitivity and identifiability analysis to determine the ability of the model to estirmine whether it can distinguish between thymidine transport and retention. RESULTS: Sensitivity and identifiability analysis suggested that the non-CO2 metabolite parameters could be fixed without significantly affecting thymidine parameter estimation. Simulations showed that K1t and KTdR could be estimated accurately (r = .97 and .98 for estimated vs. true parameters) with standard errors < 15%. The model was able to separate increased transport from increased retention associated with tumor proliferation. CONCLUSION: Our model adequately describes normal brain and brain tumor kinetics for thymidine and its metabolites, and it can provide an estimate of the rate of cellular proliferation in brain tumors.
UNLABELLED: 2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. We previously described and validated a five-compartment model for thymidine incorporation into DNA in somatic tissues, but the effect of the blood-brain barrier on the transport of TdR and its metabolites necessitated further validation before it could be applied to brain tumors. METHODS: We investigated the behavior of the model under conditions experienced in the normal brain and brain tumors, performed sensitivity and identifiability analysis to determine the ability of the model to estirmine whether it can distinguish between thymidine transport and retention. RESULTS: Sensitivity and identifiability analysis suggested that the non-CO2 metabolite parameters could be fixed without significantly affecting thymidine parameter estimation. Simulations showed that K1t and KTdR could be estimated accurately (r = .97 and .98 for estimated vs. true parameters) with standard errors < 15%. The model was able to separate increased transport from increased retention associated with tumor proliferation. CONCLUSION: Our model adequately describes normal brain and brain tumor kinetics for thymidine and its metabolites, and it can provide an estimate of the rate of cellular proliferation in brain tumors.
Authors: Robert K Doot; Mark Muzi; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; David A Mankoff Journal: J Nucl Med Date: 2010-03-17 Impact factor: 10.057
Authors: Janet F Eary; Jeanne M Link; Mark Muzi; Ernest U Conrad; David A Mankoff; Jedediah K White; Kenneth A Krohn Journal: J Nucl Med Date: 2011-03-18 Impact factor: 10.057
Authors: Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn Journal: Mol Imaging Biol Date: 2009-03-27 Impact factor: 3.488
Authors: Michael Tran Duong; Yin Jie Chen; Robert K Doot; Anthony J Young; Hsiaoju Lee; Jenny Cai; Arun Pilania; David A Wolk; Ilya M Nasrallah Journal: Nucl Med Commun Date: 2021-11-01 Impact factor: 1.690